Skip to content

Mirum Pharmaceuticals, Inc. MIRM Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.73M+58.3%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s unrealized losses on investments (before tax)?
Mirum Pharmaceuticals, Inc. (MIRM) reported unrealized losses on investments (before tax) of $121K in Q1 2026.